Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687894 | 1.00 | PARP1 (1.00) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL30331787 | 0.81 | PARP1 (0.68) | PARP1PARP10PARP11ACHE | |
| SCHEMBL9475196 | 0.81 | PARP1 (0.68) | PARP1PARP10PARP11ACHE | |
| SCHEMBL7582290 | 0.79 | PARP1 (0.65) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL797996 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL5073463 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL9447443 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11ACHE | |
| SCHEMBL6421827 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL830807 | 0.78 | PARP1 (1.00) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL8118685 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216115-A1 | METHODS FOR PRODUCING A SUPER CENTRAL MEMORY CD8 T CELL SUBTYPE BY POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITION AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-31 | — | — | US | claimed |
| US-20090270377-A1 | COMBINATION CANCER CHEMOTHERAPY | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-29 | — | — | US | claimed |
| WO-2007137000-A2 | COMBINATION CANCER CHEMOTHERAPY | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-11-29 | — | — | WO | claimed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | claimed |
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH Zürich (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-4694883-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250243486-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001091796-A2 | METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP10 14/4885PARP11 4/4885 |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | PARP1 1/4885PARP10 14/4885PARP11 9/4885 |
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | FN1, ASNS, FNIP1 | PARP1 2788/4885PARP10 2317/4885PARP11 1778/4885 |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | PARP1 2/4885PARP10 15/4885PARP11 7/4885 |
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | PARP1, PARP3, PARP11 | PARP1 1/4885PARP10 4/4885PARP11 3/4885 |
| US-20090270377-A1 | COMBINATION CANCER CHEMOTHERAPY | NCL, NSUN3, NOP58 | PARP1 118/4885PARP10 517/4885PARP11 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.